Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better

被引：0
|
作者：
Franchini, Massimo [1 ]
机构：
[1] Azienda Osped Univ Parma, Serv Immunoematol & Trasfus, Parma, Italy
来源：
BLOOD TRANSFUSION | 2010年 / 8卷 / 04期
关键词：
PREVIOUSLY UNTREATED PATIENTS; IMMUNE TOLERANCE INDUCTION; INHIBITOR DEVELOPMENT; CHILDREN; PURITY; EPIDEMIOLOGY; PRODUCTS; EFFICACY; COMPLEX; RISK;
D O I：
10.2450/2010.0067.10
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：292 / 296
页数：5
相关论文
共 50 条
  • [1] Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better
    Mannucci, Pier Mannuccio
    BLOOD TRANSFUSION, 2010, 8 (04) : 288 - 291
  • [2] Plasma-derived versus recombinant factor VIII for the treatment of hemophilia A
    Kasper, CK
    VOX SANGUINIS, 1996, 70 : 17 - 20
  • [3] Inhibitor development and efficacy of recombinant vs. plasma-derived factor VIII concentrates in haemophilia A patients
    Siegmund, B.
    Richter, H.
    Pollmann, H.
    Orlovic, M.
    Gottstein, S. .
    Klamroth, R.
    HAEMOPHILIA, 2008, 14 : 51 - 51
  • [4] Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates
    Scharrer, I
    Bray, GL
    Neutzling, O
    HAEMOPHILIA, 1999, 5 (03) : 145 - 154
  • [5] Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates
    Lin, Y
    Yang, X
    Chevrier, MC
    Craven, S
    Barrowcliffe, TW
    Lemieux, R
    Ofosu, FA
    HAEMOPHILIA, 2004, 10 (05) : 459 - 469
  • [6] Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates
    Dingli, D
    Gastineau, DA
    Gilchrist, GS
    Nichols, WL
    Wilke, JL
    HAEMOPHILIA, 2002, 8 (05) : 629 - 634
  • [7] Lower inhibitor risk of plasma-derived factor VIII concentrates versus recombinant factor VIII concentrates in patients with severe haemophilia A : result from SIPPET study and comments
    Biron-Andreani, Christine
    Diaz, Isabelle
    Navarro, Robert
    Schved, Jean-Francois
    HEMATOLOGIE, 2019, 25 (02): : 93 - 99
  • [8] Factor VIII safety: plasma-derived versus recombinant products
    Gringeri, Alessandro
    BLOOD TRANSFUSION, 2011, 9 (04) : 366 - 370
  • [9] Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis
    Peyvandi, F.
    Cannavo, A.
    Garagiola, I.
    Palla, R.
    Mannucci, P. M.
    Rosendaal, F. R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (01) : 39 - 43
  • [10] Pharmacokinetics of recombinant and plasma-derived factor VIII products in paediatric patients with severe haemophilia A
    Steele, M. R.
    Nagel, K.
    Chan, A. K. C.
    HAEMOPHILIA, 2014, 20 (01) : E100 - E101
12345